YC S20
Nabla Bio
We use AI to design antibodies for intractable diseases
About
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
Founders
- Frances Anastassacos
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Nabla Bio.
See family office activityIndustry & Focus
HealthcareDrug Discovery and DeliveryAI-powered Drug Discovery